Efficacy and Safety of T-817MA in Patients With Mild to Moderate Alzheimer's Disease (US202)
Status:
Completed
Trial end date:
2017-05-05
Target enrollment:
Participant gender:
Summary
The primary objective is to evaluate the efficacy of T-817MA as measured by ADAS-cog and
ADCS-CGIC.
The secondary objectives are:
- To evaluate the safety and tolerability of T-817MA measured by clinical safety
laboratories, physical examinations, ECGs and solicitation of adverse events.
- To evaluate the efficacy of T-817MA as measured by ADCS-ADL, FAQ, Neuropsychiatric
Inventory (NPI) and Mini-mental State Examination (MMSE).
Phase:
Phase 2
Details
Lead Sponsor:
FUJIFILM Toyama Chemical Co., Ltd. Toyama Chemical Co., Ltd.